bluebird bio, Inc. News Releases http://investor.bluebirdbio.com/ bluebird bio, Inc. News Releases en bluebird bio Presents New Data for LentiGlobin® Gene Therapy for Sickle Cell Disease (SCD) at 24th European Hematology Association (EHA) Congress http://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-presents-new-data-lentiglobinr-gene-therapy-sickle In patients who were at least six months post-treatment with LentiGlobin for SCD, median level of abnormal sickle hemoglobin (HbS) was reduced to ≤50 percent of total Hb At up to 15 months post-treatment with LentiGlobin, there were no reports of serious vaso-occlusive crisis or acute chest Fri, 14 Jun 2019 05:31:00 -0400 bluebird bio, Inc. News Releases 12436 bluebird bio Presents Long-Term Efficacy and Safety Data from Clinical Studies of LentiGlobin® Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) at 24th European Hematology Association (EHA) Congress http://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-presents-long-term-efficacy-and-safety-data Up to 3.8 years of transfusion independence in Phase 1/2 Northstar (HGB-204) study in patients with TDT who do not have a β 0 /β 0 genotype Four of five evaluable patients achieved transfusion independence in ongoing Phase 3 Northstar-2 (HGB-207) study of patients with TDT who do not have a β 0 /β Fri, 14 Jun 2019 05:31:00 -0400 bluebird bio, Inc. News Releases 12431 bluebird bio Announces Live Webcast of EHA Data Review and ZYNTEGLO® (autologous CD34+ cells encoding βA-T87Q-globin gene) Approval http://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-live-webcast-eha-data-review-and CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 6, 2019-- bluebird bio, Inc . (Nasdaq: BLUE) today announced that the company will host a live webcast to review new data presented at the European Hematology Association (EHA) Annual Meeting, and to discuss the approval of ZYNTEGLO ® (autologous CD34+ cells Thu, 06 Jun 2019 17:04:00 -0400 bluebird bio, Inc. News Releases 12366 bluebird bio Announces EU Conditional Marketing Authorization for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype http://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-eu-conditional-marketing-authorization ZYNTEGLO is the first gene therapy approved for transfusion-dependent β-thalassemia (TDT) European marketing authorization for ZYNTEGLO follows the fastest assessment of an advanced therapy medicinal product (ATMP) as part of the European Medicines Agency’s Priority Medicines (PRIME) program Mon, 03 Jun 2019 09:25:00 -0400 bluebird bio, Inc. News Releases 12351 bluebird bio Announces Investor Events in June http://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-investor-events-june-0 CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 31, 2019-- bluebird bio, Inc . (Nasdaq: BLUE) today announced that the Company will hold a conference call to discuss data presented at the European Hematology Association (EHA) Annual Meeting on Friday, June 14 at 8:00 am ET . Fri, 31 May 2019 08:00:00 -0400 bluebird bio, Inc. News Releases 12331 bluebird bio to Present New Data from Clinical Studies of LentiGlobin™ Gene Therapy for Transfusion-Dependent β-thalassemia (TDT) and LentiGlobin Gene Therapy for Sickle Cell Disease (SCD) at the 24th EHA Congress http://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-present-new-data-clinical-studies-lentiglobintm-0 Additional follow-up from the completed Phase 1/2 Northstar (HGB-204) study of LentiGlobin in adolescents and adults with TDT New data from ongoing Phase 3 Northstar-2 (HGB-207) study of LentiGlobin for TDT in patients who do not have β 0 /β 0 genotype and Phase 3 Northstar-3 (HGB-212) of patients Thu, 16 May 2019 09:12:00 -0400 bluebird bio, Inc. News Releases 12306 bluebird bio’s Analyst Day Highlights Commercial Path to Patients and Research Engine Focused on Next-Generation Gene and Cell Therapies http://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bios-analyst-day-highlights-commercial-path-patients New Collaboration with Seattle Children’s Research Institute Targets New Immunotherapy Approaches to Acute Myeloid Leukemia Phase 1/2 Study for Merkel Cell Carcinoma Planned with Fred Hutchinson Cancer Research Center Additional Preclinical Programs Across Both the Severe Genetic Disease and Thu, 09 May 2019 06:30:00 -0400 bluebird bio, Inc. News Releases 12286 bluebird bio Announces Investor Events in May http://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-investor-events-may CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 3, 2019-- bluebird bio, Inc . (Nasdaq: BLUE) today announced that the Company will host an Analyst Day, Thursday, May 9 , at 8:30 am ET at The Maxwell Hotel NYC , New York, NY . In addition, members of the management team will present at the Bank of America Fri, 03 May 2019 08:00:00 -0400 bluebird bio, Inc. News Releases 12266 bluebird bio Reports First Quarter 2019 Financial Results and Highlights Operational Progress http://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-reports-first-quarter-2019-financial-results-and – Received positive opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding β A-T87Q -globin gene) gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia (TDT) who do not have β 0 /β 0 genotype – – Company hosting Analyst Day on May 9, 2019 focused on Thu, 02 May 2019 16:05:00 -0400 bluebird bio, Inc. News Releases 12251 Celgene Corporation and bluebird bio Announce Results from Ongoing Multicenter Phase 1 Study of bb2121 anti-BCMA CAR T Cell Therapy in Patients with Multiple Myeloma Published in New England Journal of Medicine http://investor.bluebirdbio.com/news-releases/news-release-details/celgene-corporation-and-bluebird-bio-announce-results-ongoing SUMMIT, N.J. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 1, 2019-- Celgene Corporation (Nasdaq: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that the New England Journal of Medicine (NEJM) has published interim results from CRB-401, the ongoing phase 1 study of bb2121, the companies’ Wed, 01 May 2019 17:01:00 -0400 bluebird bio, Inc. News Releases 12241